Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 4/20 | 0.45 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974068 | 0.93 | KDM4E (0.42) | KDM4EPOLBF10ECE1SMN1; SMN2 | |
| SCHEMBL976086 | 0.91 | F10 (0.47) | KDM4EPOLBF10ECE1SMN1; SMN2 | |
| SCHEMBL977067 | 0.88 | ECE1 (0.46) | F10ECE1PTGDR2MAOBABCB1 | |
| SCHEMBL975637 | 0.84 | F10 (0.43) | F10ECE1SMN1; SMN2PTGDR2MAPT | |
| SCHEMBL975282 | 0.84 | F10 (0.46) | KDM4EF10ECE1PTGDR2MAPT | |
| SCHEMBL974077 | 0.84 | KDM4E (0.41) | KDM4EPOLBSMN1; SMN2MAPTLMNA | |
| SCHEMBL973562 | 0.84 | ECE1 (0.46) | F10ECE1MAPTMAOBABCB1 | |
| SCHEMBL974750 | 0.83 | KDM4E (0.51) | KDM4EF10MAPTLMNAGLA | |
| SCHEMBL975576 | 0.80 | ECE1 (0.47) | F10ECE1PTGDR2MAOBABCB1 | |
| SCHEMBL974169 | 0.80 | SMN1; SMN2 (0.41) | KDM4EF10ECE1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235016-B1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-8394820-B2 | N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-12 | — | — | US | disclosed |
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, SLC28A2 | KDM4E 246/4885POLB 960/4885F10 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.